Participating Investors Include:
415 Capital
415 CAPITAL is a specialist venture capital firm that invests in early- and development-stage MedTech companies in Europe, the United States and Israel. We primarily invest in innovative medical device technologies addressing cardiovascular disease: the worldwide leading cause of death and the single largest cost driver in the global healthcare system. We are investors AND entrepreneurs: As investors, we have funded 45 MedTech companies in the past 28 years. As entrepreneurs, we have founded, built, and exited several successful European MedTech distribution companies.
Abingworth
Abingworth has raised 12 funds dedicated to investing in life sciences and healthcare. Our most recent, Abingworth Bioventures 7 and Abingworth Clinical Co-Development Fund, raised $315 million and $108 million respectively and are actively investing. Our venture funds invest across our broad strategic areas of venture capital, clinical co-development, VIPEs and public markets. They focus primarily on private companies but invest a percentage of their value in public companies.
Andera Partners
Andera Partners is an asset management firm specialising in Private Equity. We draw on our expertise in various areas to provide a range of well-defined investment strategies. Our goal is to provide bespoke solutions to meet the challenges faced by leaders and their development models.
Asabys Partners
Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain, Europe, UK, Switzerland and Israel in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies.
Atlantic Bridge
Atlantic Bridge is a Growth Equity Firm with a Cross Border Value Add strategy with over €950 million of assets under management across seven Funds. We invest in deep technology companies in Europe and the US. Our team is made up of successful entrepreneurs and senior technology industry executives and we invest in strong ambitious entrepreneurs and management teams that have the passion and drive to scale up and exploit major growth opportunities. We help our portfolio companies expand and grow internationally through our global platform with our team and offices in London, Dublin, Munich, Paris and Palo Alto.
Atlantic Bridge University Bridge Fund
We invest in entrepreneurs with the ambition to create world-class companies of scale .A €60m investment fund to accelerate the commercialisation of ground-breaking research and the scaling of global businesses. We seek to invest in companies built from research generated at all Irish universities and third level institutions.
Broadview Ventures
Broadview is a mission-driven fund whose primary investment goal is to improve human health in the areas of cardiovascular disease and stroke. We define success – return on mission – as improving human health by bringing innovative technologies to patients. With 37 such investments over the past 9 years, Broadview has considerable experience in the seed/early-stage space, and its investment model is demonstrating early signs of success.
Bom Brabant Ventures
BOM is an economic development company that works as a growth accelerator for companies in Brabant. The BOM looks at the economic opportunities and also explicitly at the social added value of companies, such as growth of employment, CO2 reduction and sustainable production. BOM does this by sharing knowledge, forming networks and providing capital.
Cukierman & Co. Life Sciences
Cukierman & Co. Life Sciences (CLS) provides services to companies across the Life Sciences spectrum including biotechnology, pharmaceuticals, medical devices and e-health technologies. Established in 2006 as the Life Sciences Corporate Finance arm of Cukierman & Co, CLS offers investment banking services to private and public companies at different stages of their development cycle, across the whole healthcare spectrum.
Deerfield Management
Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment and philanthropy—all toward the end goal of cures for disease, improved quality of life and reduced cost of care. As of June 2020, the firm manages nearly $10 billion in assets. Providing value beyond capital, Deerfield generally maintains a combined portfolio of more than 200 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.
Earlybird Venture Capital
Founded in 1997, Earlybird invests in all development and growth phases of technology companies. Among the most experienced venture investors in Europe, Earlybird offers its portfolio companies not only financial resources, but also strategic and operational support, as well as access to an international network and capital markets. With over EUR 1 billion under management, seven IPOs and 24 trade sales, Earlybird is one of the most successful venture capital firms in Europe.
Elkstone Partners
Elkstone is a Multi-Family Office regulated by the Irish Central Bank to provide investment services including investment portfolio management, and providing compelling investment opportunities in venture, real estate and alternatives.
Endeavour Vision
Endeavour Vision is a leading private equity firm investing in growth-stage medtech and digital health companies. We invest in medical innovation that provides superior clinical benefits for patients or brings significant efficiencies to over-stretched healthcare systems. Our team offers strategic and operational expertise, extensive international experience, and a proven track record of successful exits. Endeavour Vision’s offices are in Geneva, Switzerland and Minneapolis, U.S. For more information, visit www.endeavourvision.com.
Fountain Healthcare Partners
We are a venture fund providing risk capital and expertise to ambitious entrepreneurs building outstanding life sciences companies. By limiting the number of active portfolio companies we have the bandwidth to provide more than just capital. Our years of experience help entrepreneurs grow smartly, mitigate risk and expand impact.
Fresenius Medical Care Ventures
Fresenius Medical Care Ventures was established to invest in start-ups and early-stage companies in the healthcare sector. The investments are targeted to support Fresenius Medical Care’s corporate strategy to grow continuously in our core business and to expand into new business areas. Fresenius Medical Care Ventures is complementing the corporate activities in external innovation.
Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. It has over €800 million ($1 billion) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcare services across Europe and the US.
Gimv
Gimv is a European investment company, listed on Euronext Brussels. With 40 years' experience in private equity, Gimv currently has EUR 2 billion of assets under management. The portfolio contains around 50 portfolio companies, with a combined turnover of EUR 2.5 billion and 14,000 employees.
Industrifonden
Industrifonden is a Nordic venture capital investor, focusing on early stage technology and life science companies with international potential. Industrifonden is an evergreen fund with SEK 5 billion ($600 m) in assets, and we like to work long term with the team we invest in. The tech portfolio currently consists of 25 companies, among those Barnebys, Soundtrack Your Brand and Fishbrain. The life science portfolio currently represents 14 companies, among those AMRA, BONESUPPORT and Oncopeptides.
Innogest
Innogest is a Venture Capital firm focused on seed and early stage ventures, with more than € 200 milion of capital under management. We have over 100 years of cumulative professional experience in the digital and the healthcare fields. Innogest invests in high potential companies through a direct share in their equity and pays special attention to market potential and size. Innogest leverages its extensive network of contacts, working alongside its partners through its offices in Turin, Milan and San Francisco. Our mission is to generate high-level returns for our investors by turning entrepreneurship and technology into fast-growing and successful companies.
IPF Partners
IPF Partners is a leading alternative financing provider focused on the healthcare sector. IPF Partners invests directly in emerging commercial stage pharma/biotech, medtech, diagnostics and IT healthcare companies. IPF Partners provides customised low- to non-dilutive debt and equity financing to market leading healthcare companies. The focus is on innovating products at commercial stage with a high potential in attractive markets. Typical deal size ranges from €5-20m+ over a 3- to 6-year duration.
KCK Group
KCK invests in medical technology companies with differentiated products that are well positioned to disrupt or create large markets utilizing strong management teams and business models. Our primary focus for new investments is on later stage venture and growth capital opportunities.
Kreos Capital
As the pioneer growth debt provider across the UK, Western Europe, Scandinavia and Israel, Kreos has completed over 570 portfolio company transactions and committed more than €2.6 billion in 16 different countries. Kreos has a proven track record of adding value to portfolio companies and helping them to grow with additional capital and flexibility throughout their business cycle whilst working closely with both the portfolio company management team and their equity sponsors.
Lightstone Ventures
Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing in breakthrough life science companies during a time of unique opportunity in the space. Members of the Lightstone team manage a portfolio of 50+ medical device and biotechnology companies across the ATV and Morgenthaler legacy funds (Legacy Funds).
LSP
LSP is one of Europe’s largest and most experienced healthcare investment firms. With a track record going back more than 30 years, we have built up an investment house that is dedicated to only one task: seeking, nurturing and growing healthcare investment opportunities with the potential to have a positive impact on society. We believe such opportunities create the most value for all parties.
Medtronic Ventures
Description coming soon!
MVM Partners
MVM has been investing in high growth healthcare businesses since 1997. We have a broad, global, investment remit including medical technology, pharmaceuticals, biotechnology, diagnostics, life science tools, and digital health, supported by our investment teams in Boston and London.
NEA New Enterprise Associates
New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With more than $23 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 230 portfolio company IPOs and more than 390 acquisitions.
Norgine Ventures
Norgine Ventures was started in 2012 to diversify Norgine’s activities and foster innovation in the healthcare sector. Norgine Ventures provides debt and debt-like financing to innovative, fast-growing companies in the fields of healthcare and life sciences, in Europe and the US. To date, Norgine Ventures has invested in a number of businesses, including specialty pharma, diagnostic and medical device companies, at various stages of their life cycle, both in Europe and in the US.
NRW.BANK
NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the Federal Republic of Germany and the European Union and combines them with its own equity and debt products and advisory services.
Panakes Partners
Panakes Partners is a Venture Capital investor that finances medical companies, early stage startup and SMEs, with extremely promising products and great ambition, in Europe and Israel. Thanks to our strong entrepreneurial and financial experiences we provide more than capital, and we aim to work together with entrepreneurs to develop successful businesses as an active and well-connected investor. We also have strong relationship with selected industrial partners to help companies to accelerate their development. We seek and help to grow Medtech companies with the potential to have a positive impact on society. We believe such opportunities create the most value for all parties.
PMV
PMV is a do and dare company that is shaping the future of the Flemish economy. It finances promising companies from the very start up to and including growth and internationalization. With and for the government and other partners, she realizes projects that are important for prosperity and well-being in Flanders.
Santé Ventures
Santé invests at the leading edge of innovation in healthcare and technology. We manage over a half-billion dollars of capital in two separate strategies. Combining extensive healthcare industry experience with deep scientific and technology expertise, we pursue innovative new opportunities with attractive potential returns.
Seroba
Seroba is a European life sciences venture capital firm focused on investing in winning innovations in biotech and medtech. The team has deep investment and industry experience enabling Seroba to help entrepreneurs realise their ambitions whilst creating value for investors. The firm has three funds under management and has built a portfolio of investee companies across multiple indications. Seroba partners with entrepreneurs to create and build businesses around extraordinary science. Follow our story at www.seroba-lifesciences.com.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of over 40 professionals from all over Europe, the U.S., and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed over 500 companies over five decades, creating market leaders around the globe. Today, Sofinnova Partners has over €2 billion under management.
Sonder Capital
The Sonder Capital team has spent our entire careers dedicated to the medtech community. As entrepreneurs, operators and investors we’ve built, funded, and advised companies creating entire new categories of healthcare. Our goal is to partner with entrepreneurs who have a passion for inventing technologies capable of transforming healthcare in the medical device, diagnostic and healthtech sectors. We commit our energy and capital early (seed or Series A) and maintain guidance and support from inception to acquisition or IPO.
Thuja Capital
Thuja Capital is an early-stage venture capital firm located in Utrecht, The Netherlands. We invest in product focused companies that aim to have true impact for patients and doctors alike, as demonstrated in clinical studies to enable a health claim. Hence most of our ventures are active in the field of therapeutics, medical devices and digital health. Not only do we invest, we also take an active role in helping the company to become successful, by leveraging our extensive network and by bringing our own experience to the table.
Treo Ventures
We focus on medical technology investments in companies targeting large unmet clinical needs. We will invest in high growth areas and in companies solving major clinical problems while balancing that with focused capital efficient development plans. We take a balanced approach in building our portfolio with some early stage investments, where the prior seed stage investment has proved the feasibility of a concept, and some later stage investments, where clinical data has shown efficacy and the company is in a “scale-up for commercialization” mode.
Valiance
Valiance Asset Management is a leading global Life Sciences investor focused on addressing the unmet needs of a growing and ageing population, delivering strong upside for our investors whilst also generating significant health economics and improving people’s lives.
Wellington Partners
Since 1998, Wellington Partners has been a leading European Venture Capital firm investing in early- and growth-stage Life Science companies, active in the fields of Therapeutics, Medical Technology, Diagnostics, Digital Health, and Industrial Biotechnology. Managing and investing out of funds WPLS-III, WPLS-IV and WPLS-V. More than €400m of funds raised dedicated to Life Sciences. Investment Team with strong clinical, scientific and operational backgrounds. Europe, special circumstances US, leader in Germany. Seed to late-stage, private companies most of the time. Ticket sizes from €2m up to €20m over the life of the investment.
Westlake Accelerator
Westlake Cross Border Innovation Accelerator aims at building a superior cross-border innovation eco-system, and bridging innovative projects, creative talents and venture resources. Our program helps early-and-growth stage technology-driven startups building their future from 0 to 1 in the fields of Healthcare, Fintech, Big Data, IoTs, Artificial Intelligence, and Robotics, etc.
